Vascular endothelial growth factor (VEGF) fails to improve blood flow and to promote collateralization in a diabetic mouse ischemic hindlimb model
Angiogenic therapy with vascular endothelial growth factor (VEGF) has been proposed as a treatment paradigm for patients suffering from an insufficiency of collateral vessels. Diabetes is associated with increase in the production of VEGF and therefore additional VEGF may not be beneficial. Accordingly, we sought to determine the efficacy of VEGF therapy to augment collateral formation and tissue perfusion in a diabetic mouse ischemic hindlimb model.
Diabetic and non-diabetic mice were studied in parallel for the efficacy of VEGF administration. Diabetes was induced with streptozotocin. Hindlimb ischemia was produced by severing the left iliac artery. An outlet tube from an osmotic infusion pump with placebo/ 500 micrograms of plasmid-DNA encoding VEGF was fenestrated and tunneled into the left quadriceps muscle.
VEGF induced more rapid and complete restoration of blood flow in normal mice. However, in the setting of diabetes there was no difference between VEGF Vs. placebo in the rate or adequacy of flow restoration. There was a significant increase in smooth muscle actin and Factor-VIII antigen densities in diabetic animals and in animals which received VEGF.
Angiogenic therapy with VEGF in the setting of diabetes does not appear to have the beneficial effects seen in the absence of diabetes.
- Freedman S, Isner JM: Therapeutic angiogenesis for ischemic cardiovascular disease. J Mol Cell Cardiol 2001, 33:379–393. CrossRef
- Schaper W, Ito WD: Molecular mechanisms of coronary collateral vessel growth. Circ Res 1996, 79:911–919.
- Hammond HK, McKirnan MD: Angiogenic gene therapy for heart disease: a review of animal studies and clinical trials. Cardiovasc Res 2001, 49:561–567. CrossRef
- Simons M, Bonow RO, Chronos NA, Cohen DJ, Giordano FJ, Hammond HK, Laham RJ, Li W, Pike M, Sellke FW: Clinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus An Expert Panel Summary. Circulation 2000, 102:e73-e86.
- Ferrara N: Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999, 56:794–814. CrossRef
- Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 6:389–395. CrossRef
- Waltenberger J, Lange J, Kranz A: Vascular endothelial growth factor-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus. A potential predictor for the individual capacity to develop collaterals. Circulation 2000, 102:185–190.
- Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H, Ergin A: Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999, 99:2239–2242.
- Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA: Pharmacological treatment of coronary artery disease with recombinant FGF-2. Circulation 2002, 105:788–793. CrossRef
- Roguin A, Avivi A, Nitecki S, Rubinstein I, Levy NS, Abassi ZA, Resnick MB, Lache O, Melamed-Frank M, Joel A, et al.: Restoration of blood flow by using continuous perimuscular infiltration of plasmid DNA encoding subterranean mole rat Spalax ehrenbergi VEGF. Proc Natl Acad Sci USA 2003, 100:4644–4648. CrossRef
- Avivi A, Resnick MB, Nevo E, Joel A, Levy AP: Adaptive hypoxic tolerance in the subterranean mole rat Spalax ehrenbergi: the role of vascular endothelial growth factor. FEBS Lett 1999, 452:133–140. CrossRef
- Leahy MJ, de Mul FF, Nilsson GE, Maniewski R: Principles and practice of the laser-Doppler perfusion technique. Technol Health Care 1999, 7:143–162.
- Rubinstein I, Abassi Z, Coleman R, Milman F, Winaver J, Better OS: Involvement of nitric oxide system in experimental muscle crush injury. J Clin Invest 1998, 101:1325–1333. CrossRef
- Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B, Peters K, Isner JM.: Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999, 154:355–363.
- Waltenberger J: Impaired collateral vessel development in diabetes; potential mechanisms and therapuetic implications. Cardiovasc Res 2001, 49:554–590. CrossRef
- Cooper RG, Taylor CM, Choo JJ, Weiss JB: Elevated endothelial-cell-stimulating angiogenic factor activity in rodent glycolytic skeletal muscles. Clin Sci (Lond) 1991, 81:267–270.
- Taniyama Y, Morishita R, Hiraoka K, Aoki M, Nakagami H, Yamasaki K, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T: Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model – molecular mechanisms of delayed angiogenesis in diabetes. Circulation 2001, 104:2344–2350. CrossRef
- Williams B, Gallacher B, Patel H, Orme CL: Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997, 46:1497–1503. CrossRef
- Edward M, Conway EM, Collen D, Carmeliet P: Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001, 49:507–521. CrossRef
- Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC: Human Endothelial Progenitor Cells From Type II Diabetics Exhibit Impaired Proliferation, Adhesion, and Incorporation Into Vascular Structures. Circulation 2002, 106:2781–2786. CrossRef
- Vascular endothelial growth factor (VEGF) fails to improve blood flow and to promote collateralization in a diabetic mouse ischemic hindlimb model
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
- Online Date
- December 2003
- Online ISSN
- BioMed Central
- Additional Links
- Author Affiliations
- 1. Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, 31096, Israel
- 2. Department of Cardiology, Rambam Medical Center, Bat Galim, Haifa, 31096, Israel
- 6. Division of Cardiology, The Johns Hopkins Hospital, Traylor 903, 720 Rutland Ave., Baltimore, MD, 21205, USA
- 3. Department of Vascular Surgery, Rambam Medical Center, Bat Galim, Haifa, 31096, Israel
- 5. Institute of Evolution, University of Haifa, 31095, Haifa, Israel
- 4. Department of Pathology, Lady Davis Carmel Medical Center, 7 Michal St, Haifa, Israel, 34362